Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

Sara Capolla, Chiara Garrovo, Sonia Zorzet, Andrea Lorenzon, Enrico Rampazzo, Ruben Spretz, Gabriele Pozzato, Luis Núñez, Claudio Tripodo, Paolo Macor, Stefania Biffi

Research output: Contribution to journalArticlepeer-review


The expectations of nanoparticle (NP)-based targeted drug delivery systems in cancer, when compared with convectional therapeutic methods, are greater efficacy and reduced drug side effects due to specific cellular-level interactions. However, there are conficting literature reports on enhanced tumor accumulation of targeted NPs, which is essential for translating their applications as improved drug-delivery systems and contrast agents in cancer imaging. In this study, we characterized biodegradable NPs conjugated with an anti-CD20 antibody for in vivo imaging and drug delivery onto tumor cells. NPs’ binding specificity mediated by anti-CD20 antibody was evaluated on MEC1 cells and chronic lymphocytic leukemia patients’ cells. The whole-body distribution of untargeted NPs and anti-CD20 NPs were compared by time-domain optical imaging in a localized human/mouse model of B-cell malignancy. These studies provided evidence that NPs’ functionalization by an anti-CD20 antibody improves tumor pharmacoki-netic profiles in vivo after systemic administration and increases in vivo imaging of tumor mass compared to non-targeted NPs. Together, drug delivery and imaging probe represents a promising theranostics tool for targeting B-cell malignancies.

Original languageEnglish
Pages (from-to)4099-4109
Number of pages11
JournalInternational Journal of Nanomedicine
Publication statusPublished - Jun 22 2015


  • Active targeting
  • Optical imaging
  • Tumor accumulation

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Organic Chemistry
  • Drug Discovery


Dive into the research topics of 'Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies'. Together they form a unique fingerprint.

Cite this